Home   |  Contact   
.: ELTE TPIK :.
C e n t e r   f o r  I n n o v a t i o n  ,  T e c h n o l o g y   T r a n s f e r    a n d    G r a n t   A f f a i r s
4
.: Eötvös Loránd Tudományegyetem :.
.: Új Széchenyi Terv :.
.: EURÓPAI UNIÓ :.
.: TÁMOP-4.2.1-09/1/KMR-2009-0001 :.
.: Magyarország megújul :.
.: Nemzeti Fejlesztési Ügynökség :.
.: Európai Szociális Alap :.
    »   Men     »   News-events
   

ELTE success in biotechnology


Budapest, Hungary, and Zug, Switzerland (September 8, 2014) – ImmunoGenes AG, a biopharmaceutical company that specializes in the generation of transgenic animals for discovery of antibodies against challenging targets, today announced that Kyowa Hakko Kirin Co., Ltd., Japan (KHK) has acquired a non-exclusive license to use the company’s genetically-modified animals for the research, development and commercialization of therapeutic antibodies. Under the terms of the non‐exclusive license, KHK will be able to use the company's FcRn-overexpressing transgenic mice (the IMG-AbS™ technology platform) to generate antibodies. ImmunoGenes has previously published extensively on the demonstrated ability of the company's IMG-AbS™ technology platform to improve antigen presentation and generate increased antibody diversity leading to antibody development against weakly immunogenic targets, like GPCR molecules.

“KHK is a global leader in the discovery and development of innovative therapeutic antibodies,” said Hiroshi Okazaki, Ph.D., Executive Officer, Vice President, Head, R&D Division of KHK. “We believe that the ImmunoGenes IMG-AbS™ technology platform is a significant advance that will accelerate our antibody discovery efforts and increase our ability to generate therapeutic antibodies.”

“We are delighted by the interest of KHK in our technology which we have shown offers the ability to achieve superior antibody generating results against antigens that are of significant interest to developers of novel therapeutics and diagnostics,” said Imre Kacskovics, Chief Executive Officer of ImmunoGenes. “We are excited that a company like KHK, which is a proven pioneer in the development of antibody-based therapeutics, has selected the ImmunoGenes IMG-AbS™ technology platform to use in the antibody research and development.”

About Kyowa Hakko Kirin
Kyowa Hakko Kirin Co., Ltd. is a leading biopharmaceutical company in Japan focusing on its core business area of oncology, nephrology and immunology/allergy. Kyowa Hakko Kirin leverages antibody-related leading-edge technologies to discover and develop innovative new drugs aiming to become a global specialty pharmaceutical company which contributes to the health and well-being of people around the world. For more information, visit http://www.kyowa-kirin.com.

.:   Portlkezelői men  •   Tartalom mdostsa  •  Last mod. date: 2014.09.12.   :.
July 2017.
M Tu W Th F Sa Su
26 27 28 29 30 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31 1 2 3 4 5 6

ELTE Innovative Education Forum and SIMple exhibition
The ELTE Innovative Education Forum is an event for sharing experiences, discussing opportunities for wider use of innovative education methods and exploring barriers. SIMpLe project aims to boost innovation potential of participating universities. The interactive and online exhibition will provide some inspiration, idea that can support education. Details »
SIMpLe project launched
The Eotvos Lorand University, the Bergen University College and the BusinessWorks Ltd. launched together a project with the cooperation of the Central European University as an external partner, in order to raise awareness on these aspects, to improve competencies and to develop a thorough and effective entrepreneurial curriculum in particular for non-business students. Details »
ELTE PIK and EIT ICT Labs workshop was successfully launched
The first of a series of creative workshops, attended by 17 doctoral students, was organised on 19 June 2014 by ELTE Center for Innovation and Grant Affairs and EIT ICT Labs Budapest Associate Partner Group. Details »
ELTE success in biotechnology
On 8' September ImmunoGenes AG announced that Kyowa Hakko Kirin Co., Ltd., Japan (KHK) has acquired a non-exclusive license to use the company's genetically-modified animals for the research, development and commercialization of therapeutic antibodies Details »
ELTE Hackathon-in-a-box
Hackathon-in-a-box is searching for the best ideas!
Join our innovation contest at the EIT ICT Labs Budapest Co-Location Centre!
Details »
Film Up! – Short Film Competition
Eotvos Lorand University and Inforpark Foundation have announced its call for short films that highlight students’ research activities. Details »
  .:  I I G  W G . I W D G :.
4
  © 2012-2015 Etvs Lornd University - Center for Innovation   All rights reserved.   
   Address :: Szerb street 21-23. Budapest, 1056 Hungary,       Phone :: +36 1 485 5246      E-mail :: palyazat@rekthiv.elte.hu